IBCC - Instituto Brasileiro de Controle do Câncer

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Metastatic breast cancer3 trials
• Colorectal cancer1 trial
• Melanoma1 trial
• Prostate cancer1 trial
• Sarcoma1 trial
• Thyroid cancer1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Pfizer3 trials
• Bayer2 trials
• Daiichi Sankyo1 trial
• EMD Serono Research & Development Institute, Inc.1 trial

Running trials

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting

Closed trials

• Completed

  Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

  NCT04736199· Phase 3· Bayer· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

  NCT02576431· Phase 2· Bayer· Source